See also this year's filing and all EDGAR filings for this company.
PDF Report 0001349929_2019_Vyant_Bio_Inc.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.3832674319357592, 'aggregate_val': 35406000, 'exp_sum': 57409000, 'exp_to_value': {'IntangibleAssets': 17257000, 'AssetsNonCurrent': 22003000, 'AssetsCurrent': 9347000, 'PropertyPlantAndEquipment': 4056000, 'remainder_Assets': 4746000}} |
Graph
Absolute values for 0001349929, Vyant Bio Inc.
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 17,257,000 |
| 1 | AssetsNonCurrent | 22,003,000 |
| 2 | AssetsCurrent | 9,347,000 |
| 3 | PropertyPlantAndEquipment | 4,056,000 |
| 4 | remainder_Assets | -17,257,000 |
| 5 | LongTermLiabilities | 0 |
| 6 | LiabilitiesCurrent | 27,293,000 |
| 7 | remainder_Liabilities | 1,311,000 |
| 8 | LaborExpense | 0 |
| 9 | CostOfGoodsAndServicesSold | 18,724,000 |
| 10 | GeneralAndAdministrativeExpense | 19,184,000 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 0 |
| 13 | DepreciationDepletionAndAmortization | 0 |
| 14 | SellingAndMarketingExpense | 5,268,000 |
| 15 | ResearchAndDevelopmentExpense | 2,488,000 |
| 16 | remainder_Expenses | 3,784,000 |
| 17 | remainder_Revenues | 27,470,000 |
| 18 | remainder_NetIncome | 1,605,000 |
| 19 | remainder_ComprehensiveNetIncome | -9,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 35,406,000 |
| 1 | Liabilities | 28,604,000 |
| 2 | Expenses | 49,448,000 |
| 3 | Revenues | 27,470,000 |
| 4 | StockholdersEquity | 6,802,000 |
| 5 | NetIncome | -20,373,000 |
| 6 | ComprehensiveNetIncome | -20,382,000 |
| 7 | BaseVar | 84,228,780 |
| 8 | EconomicCapitalRatio | -0.488 |
Edgar->Model Mapping
Feature Distribution
Change over Time
